Genmab Announces Phase III Studies of Ofatumumab in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genmab Announces Phase III Studies of Ofatumumab in Relapsing Multiple Sclerosis

Company Announcement

  • Phase III trials (ASCLEPIOS I and II) with the subcutaneous formulation of ofatumumab in Relapsing Multiple Sclerosis
  • Studies expected to begin enrolling in September 2016

Copenhagen, Denmark; June 2, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its collaboration partner Novartis will start Phase III studies of the subcutaneous formulation of ofatumumab in relapsing multiple sclerosis (MS) with enrolment of patients expected to start in September 2016. The studies will compare the efficacy and safety of subcutaneous ofatumumab versus teriflunomide in patients with relapsing MS. Details of the studies will shortly become available on clinicaltrials.gov.

“Ofatumumab has the potential to be a best-in-class anti B-cell therapy for relapsing MS,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “We look forward to swift execution and outcome of these trials and to further development of ofatumumab in this disease area.”

About the ASCLEPIOS I and II studies The Phase III trials are randomized, double-blind, double-dummy studies comparing the efficacy and safety of subcutaneous ofatumumab versus teriflunomide, a standard treatment in MS, in approximately 900 patients with relapsing MS per study.  Patients will be randomized to receive either subcutaneous injections of ofatumumab every four weeks or of teriflunomide orally once daily. In order to blind for the different formulations, double-dummy masking will be used i.e. all patients will take injections (containing either active ofatumumab or placebo) and oral capsules (containing either active teriflunomide or placebo). The primary endpoint of the studies is annualized relapse rate (ARR), which is the number of confirmed relapses in a 12 month period. The studies will be conducted by Novartis.

About Multiple Sclerosis Multiple Sclerosis (MS) is an inflammatory disease of the central nervous system that affects approximately 2.5 million people worldwide. 1 MS is twice as common in females as in males, occurring with a peak incidence at the age of 30 years and incidence varies widely in different populations and ethnic groups. The etiology of MS remains unknown, but the geographic variation points towards possible environmental and genetic factors. Relapsing MS is characterized by unpredictable recurrent attacks and accounts for 80% of MS cases. 2  

About Ofatumumab Ofatumumab is a human monoclonal antibody that is designed to target the CD20 molecule found on the surface of normal B lymphocytes.

Ofatumumab is approved and marketed for intravenous use in certain chronic lymphocytic leukemia indications under the trade name Arzerra®. Please see full Prescribing Information, including Boxed WARNING for Arzerra .

Arzerra is marketed under a collaboration agreement between Genmab and Novartis. Novartis also has rights to develop ofatumumab in autoimmune indications, including multiple sclerosis.

Ofatumumab is not approved anywhere in the world as a treatment for relapsing MS.

About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com .   

Contact:           Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law. Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo ® ; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody ® and UniBody ® . Arzerra ® is a trademark of Novartis AG or its affiliates. DARZALEX ® is a trademark of Janssen Biotech, Inc.

1. GlobalData. EpiCast Report: Multiple Sclerosis – Epidemiology Forecast to 2024. Published September 2015 2. Datamonitor. Multiple Sclerosis Treatment. Published January 2015

Company Announcement no. 28 CVR no. 2102 3884

Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 34

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 48

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 79

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 85

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 37

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
YYForce Security Win Adds Recurring Singapore Revenue Base

Updated Category News Views 124

A retail-property security mandate rarely makes anyone pound the table, and frankly it should not. Still, YYForce has landed a tangible two-year contract in Singapore worth roughly S$831,120, with subsidiary Uniforce Security Services set to begin work on December 1, 2026. For NASDAQ:YFOR investors, this is the kind of small, operationally real win that deserves a sober...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 60

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 15

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 83

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
Millrose Lawsuit Puts Disclosure Discipline in Focus

Updated Category News Views 15

A supposedly clean homesite-option story has wandered into the legal weeds, and that is exactly where investors need to slow down. A shareholder class action against Millrose Properties alleges the company painted one business model for the market while pursuing a materially different one behind the curtain. That allegation has not been proven in court, and anybody...

Continue Reading

Top 5 Most Recently Viewed Articles

LootBar Enhances Game Recharge with New Security Features

Updated Category News Views 193

LootBar Redefines Game Recharge Security As players seek a secure method for discounted game top-ups, LootBar has introduced a groundbreaking self top-up feature. This innovative addition empowers gamers to conduct transactions without exposing their account passwords, presenting a safer alternative to traditional recharge methods. A Major Leap Forward in Security The...

Continue Reading
Marriott Bonvoy Unveils Unique Pet-Friendly Travel Program

Updated Category News Views 406

Introduction to the Pawssible Journey Program Marriott Bonvoy, a beloved travel program from Marriott International, is set to enchant pet owners across Greater China with the introduction of its new initiative called the "Pawssible Journey." This innovative program is founded on three primary experiences: "Paw Stay" themed accommodations, "Paw Play" social interaction...

Continue Reading
Xeriant Unveils Groundbreaking Video Showcasing Fire Safety Innovation

Updated Category News Views 155

Xeriant Highlights Innovative Fire-Retardant Technology in New Video Xeriant, Inc. (OTCQB: XERI), a pioneering company dedicated to the discovery and commercialization of advanced materials technology, has released a fascinating video that dives into the remarkable performance of their nanotech fire-retardant. This video encapsulates the power of their innovative fire...

Continue Reading
Understanding Blackstone's Recent Options Activity and Trends

Updated Category News Views 202

Blackstone's Bullish Options Environment Investors looking at Blackstone are seeing some exciting movements in the options market. These activities have been driven by significant investment interest, hinting that major players are optimistic about Blackstone's future. Insight into Trading Patterns Upon reviewing the trading history for Blackstone (NYSE: BX), multiple...

Continue Reading
Top Smart Meter Startups Spotlight: 360Quadrants Key Report

Updated Category News Views 306

360Quadrants Highlights Smart Meter Startups in 2025 360Quadrants has recently unveiled an insightful report that shines a light on the leading startups and SMEs in the smart meter industry. This comprehensive evaluation showcases both established global players and emerging innovators who are making remarkable strides in market presence, product development, and...

Continue Reading